EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Modern subcutaneous implantable defibrillator therapy in patients with cardiomyopathies and channelopathies: data from a large multicentre registry

Federico Migliore iD, Mauro Biffi iD, Stefano Viani iD, Raimondo Pittorru iD, Pietro Francia iD, Paolo Pieragnoli iD, Paolo De Filippo iD, Giovanni Bisignani, Gerardo Nigro iD, Antonio Dello Russo iD, Ennio Pisanò iD, Pietro Palmisano iD und 9 weitere

Europace · 02.08.2023 · 25 (9)

DOI: 10.1093/europace/euad239 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Europace, online erschienen am 03.08.2023. Verfasst von Federico Migliore und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac, Thoracic Vascular Sciences and Public Health, University of Padova, Padova, Italy. Hauptthemen laut MEDLINE: Defibrillators, Implantable, Channelopathies, Cardiomyopathies. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Patients with cardiomyopathies and channelopathies are usually younger and have a predominantly arrhythmia-related prognosis; they have nearly normal life expectancy thanks to the protection against sudden cardiac death provided by the implantable cardioverter defibrillator (ICD). The subcutaneous ICD (S-ICD) is an effective alternative to the transvenous ICD and has evolved over the years. This study aimed to evaluate the rate of inappropriate shocks (IS), appropriate therapies, and device-related complications in patients with cardiomyopathies and channelopathies who underwent modern S-ICD implantation. Methods and results We enrolled consecutive patients with cardiomyopathies and channelopathies who had undergone implantation of a modern S-ICD from January 2016 to December 2020 and who were followed up until December 2022. A total of 1338 S-ICD implantations were performed within the observation period. Of these patients, 628 had cardiomyopathies or channelopathies. The rate of IS at 12 months was 4.6% [95% confidence interval (CI): 2.8–6.9] in patients with cardiomyopathies and 1.1% (95% CI: 0.1–3.8) in patients with channelopathies (P = 0.032). No significant differences were noted over a median follow-up of 43 months [hazard ratio (HR): 0.76; 95% CI: 0.45–1.31; P = 0.351]. The rate of appropriate shocks at 12 months was 2.3% (95% CI: 1.1–4.1) in patients with cardiomyopathies and 2.1% (95% CI: 0.6–5.3) in patients with channelopathies (P = 1.0). The rate of device-related complications was 0.9% (95% CI: 0.3–2.3) and 3.2% (95% CI: 1.2–6.8), respectively (P = 0.074). No significant differences were noted over the entire follow-up. The need for pacing was low, occurring in 0.8% of patients.

Conclusion

Modern S-ICDs may be a valuable alternative to transvenous ICDs in patients with cardiomyopathies and channelopathies. Our findings suggest that modern S-ICD therapy carries a low rate of IS. Clinical Trial Registration URL: http://clinicaltrials.gov/Identifier: NCT02275637.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Defibrillators, ImplantableChannelopathiesCardiomyopathiesHumansTreatment OutcomeDeath, Sudden, CardiacRegistries

Stichwörter der Autor:innen

CardiomyopathiesChannelopathiesImplantable defibrillatorInappropriate shockSubcutaneous

Autor:innen und Institutionen

  • Department of Cardiac, Thoracic Vascular Sciences and Public Health, University of Padova, Padova, Italy.
  • Institute of Cardiology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Policlinico S.Orsola-Malpighi, Bologna, Italy.
  • Second Cardiology Division, Cardio-Thoracic and Vascular Department, University Hospital of Pisa, Pisa, Italy.
  • Cardiology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, University Sapienza, Rome, Italy.
  • Arrhythmic Disease Unit, University of Florence, Florence, Italy.
  • Cardiac Electrophysiology and Pacing Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy.

ORCID-Profile: Federico Migliore, Mauro Biffi, Stefano Viani, Raimondo Pittorru, Pietro Francia, Paolo Pieragnoli, Paolo De Filippo, Gerardo Nigro, Antonio Dello Russo, Ennio Pisanò, Pietro Palmisano, Antonio Rapacciuolo, Massimo Stefano Silvetti, Carlo Lavalle, Antonio Curcio, Roberto Rordorf, Sergio Valsecchi, Antonio D'Onofrio, Giovanni Luca Botto

Zitieren

APA

Migliore, F., Biffi, M., Viani, S., Pittorru, R., Francia, P., Pieragnoli, P., De Filippo, P., Bisignani, G., Nigro, G., Dello Russo, A., Pisanò, E., Palmisano, P., Rapacciuolo, A., Silvetti, M. S., Lavalle, C., Curcio, A., Rordorf, R., Lovecchio, M., Valsecchi, S., …, & Botto, G. L. (2023). Modern subcutaneous implantable defibrillator therapy in patients with cardiomyopathies and channelopathies: data from a large multicentre registry. Europace, 25(9). https://doi.org/10.1093/europace/euad239

Vancouver

Migliore F, Biffi M, Viani S, Pittorru R, Francia P, Pieragnoli P, et al. Modern subcutaneous implantable defibrillator therapy in patients with cardiomyopathies and channelopathies: data from a large multicentre registry. Europace. 2023;25(9). doi:10.1093/europace/euad239

BibTeX
@article{Migliore2023,
  author = {Migliore, Federico and Biffi, Mauro and Viani, Stefano and Pittorru, Raimondo and Francia, Pietro and Pieragnoli, Paolo and De Filippo, Paolo and Bisignani, Giovanni and Nigro, Gerardo and Dello Russo, Antonio and Pisanò, Ennio and Palmisano, Pietro and Rapacciuolo, Antonio and Silvetti, Massimo Stefano and Lavalle, Carlo and Curcio, Antonio and Rordorf, Roberto and Lovecchio, Mariolina and Valsecchi, Sergio and D'Onofrio, Antonio and Botto, Giovanni Luca},
  title = {Modern subcutaneous implantable defibrillator therapy in patients with cardiomyopathies and channelopathies: data from a large multicentre registry},
  journal = {Europace},
  year = {2023},
  volume = {25},
  number = {9},
  doi = {10.1093/europace/euad239}
}
Kostenlos starten →